Tags

Type your tag names separated by a space and hit enter

Square-wave voltammetric determination of bezafibrate in pharmaceutical formulations using a cathodically pretreated boron-doped diamond electrode.
Talanta. 2013 Jan 15; 103:201-6.T

Abstract

The determination of bezafibrate (BZF) using square-wave voltammetry (SWV) and a cathodically pretreated boron-doped diamond electrode is proposed. Cyclic voltammetry results showed one irreversible oxidation peak for BZF at 1.20 V (vs. Ag/AgCl (3.0 mol L(-1) KCl)) in a 0.04 mol L(-1) Britton-Robinson (BR) buffer solution (pH 2.0). Under optimized SWV conditions, a linear analytical curve is obtained for the BZF concentration range 0.10-9.1 μmol L(-1) in the BR buffer solution (pH 2.0), with a detection limit of 0.098 μmol L(-1). The obtained recoveries range from 93.4 to 108%. The proposed novel method was successfully applied in the determination of the BZF content in several pharmaceutical formulations (tablets) and the results are in close agreement (at a 95% confidence level) with those obtained using a comparative spectrophotometric method.

Authors+Show Affiliations

Departamento de Química, Universidade Federal de São Carlos, C.P. 676, São Carlos-SP 13560-970, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23200378

Citation

Ardila, Jorge Armando, et al. "Square-wave Voltammetric Determination of Bezafibrate in Pharmaceutical Formulations Using a Cathodically Pretreated Boron-doped Diamond Electrode." Talanta, vol. 103, 2013, pp. 201-6.
Ardila JA, Sartori ER, Rocha-Filho RC, et al. Square-wave voltammetric determination of bezafibrate in pharmaceutical formulations using a cathodically pretreated boron-doped diamond electrode. Talanta. 2013;103:201-6.
Ardila, J. A., Sartori, E. R., Rocha-Filho, R. C., & Fatibello-Filho, O. (2013). Square-wave voltammetric determination of bezafibrate in pharmaceutical formulations using a cathodically pretreated boron-doped diamond electrode. Talanta, 103, 201-6. https://doi.org/10.1016/j.talanta.2012.10.033
Ardila JA, et al. Square-wave Voltammetric Determination of Bezafibrate in Pharmaceutical Formulations Using a Cathodically Pretreated Boron-doped Diamond Electrode. Talanta. 2013 Jan 15;103:201-6. PubMed PMID: 23200378.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Square-wave voltammetric determination of bezafibrate in pharmaceutical formulations using a cathodically pretreated boron-doped diamond electrode. AU - Ardila,Jorge Armando, AU - Sartori,Elen Romão, AU - Rocha-Filho,Romeu C, AU - Fatibello-Filho,Orlando, Y1 - 2012/10/16/ PY - 2012/07/28/received PY - 2012/10/05/revised PY - 2012/10/08/accepted PY - 2012/12/4/entrez PY - 2012/12/4/pubmed PY - 2013/6/5/medline SP - 201 EP - 6 JF - Talanta JO - Talanta VL - 103 N2 - The determination of bezafibrate (BZF) using square-wave voltammetry (SWV) and a cathodically pretreated boron-doped diamond electrode is proposed. Cyclic voltammetry results showed one irreversible oxidation peak for BZF at 1.20 V (vs. Ag/AgCl (3.0 mol L(-1) KCl)) in a 0.04 mol L(-1) Britton-Robinson (BR) buffer solution (pH 2.0). Under optimized SWV conditions, a linear analytical curve is obtained for the BZF concentration range 0.10-9.1 μmol L(-1) in the BR buffer solution (pH 2.0), with a detection limit of 0.098 μmol L(-1). The obtained recoveries range from 93.4 to 108%. The proposed novel method was successfully applied in the determination of the BZF content in several pharmaceutical formulations (tablets) and the results are in close agreement (at a 95% confidence level) with those obtained using a comparative spectrophotometric method. SN - 1873-3573 UR - https://www.unboundmedicine.com/medline/citation/23200378/Square_wave_voltammetric_determination_of_bezafibrate_in_pharmaceutical_formulations_using_a_cathodically_pretreated_boron_doped_diamond_electrode_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0039-9140(12)00853-3 DB - PRIME DP - Unbound Medicine ER -